HARMONISATION – A multimodal prospective study of vascular cognitive impairment in multi-ethnic Asians: Cohort profile,progress,current contributions,and future impact
Restricted accessReview articleFirst published online December, 2025
HARMONISATION – A multimodal prospective study of vascular cognitive impairment in multi-ethnic Asians: Cohort profile,progress,current contributions,and future impact
Vascular cognitive impairment (VCI) describes cerebrovascular disease (CeVD)-associated cognitive disorders regardless of pathogenesis, ranging from a prodrome to dementia. Heterogeneity in the etiology and severity of CeVD, and significant co-occurrence with Alzheimer's disease (AD) pathology has hampered investigations. Research into VCI is especially relevant in Asia, where cognitive impairment and dementia, often due to VCI, grows due to rapidly aging populations and high prevalence of vascular risk factors. This manuscript reviewed the rationale, unique positioning, design, methodology, and findings from the HARMONISATION study, a prospective observational study of VCI and AD in multi-ethnic Asians. HARMONISATION aimed to discover and validate novel biomarkers as effective diagnostic and prognostic tools, and translate findings into improved patient care, disease management and treatment—utilizing comprehensive multimodal clinical, neuroimaging, retinal, and blood biomarker data to address critical research gaps such as the etiology and clinical importance of mixed dementia, relationships between AD and CeVD pathology, and challenges of heterogenous CeVD pathology. HARMONIZATION recruited and deeply phenotyped 700 older multi-ethnic Asians with no cognitive impairment, mild cognitive impairment, and dementia for up to 5 years of follow-up. It has yielded developments in biomarker identification, validation, interactions and analysis methods; disease mechanisms and progression; clinical prognostics for VCI and AD; improved patient care and management; and enabled future development of novel interventions in Asians, and globally. An ongoing extension study will allow up to 10 years follow-up to further explore specific modifiable processes of VCI and the contributions of vascular events to cognitive impairment.
GorelickPBScuteriABlackSE, et al.Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American stroke association. Stroke2011; 42: 2672–2713.
2.
PendleburySTRothwellPM. Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford vascular study. Lancet Neurol2019; 18: 248–258.
3.
van RooijFGKesselsRPRichardE, et al.Cognitive impairment in transient ischemic attack patients: a systematic review. Cerebrovasc Dis2016; 42: 1–9.
4.
StephanBCMatthewsFEKhawK-T, et al.Beyond mild cognitive impairment: vascular cognitive impairment, no dementia (VCIND). Alzheimers Res Ther2009; 1: 1–9.
5.
RizziLRossetIRoriz-CruzM. Global epidemiology of dementia: Alzheimer's and vascular types. Biomed Res Int2014; 2014: 908915.
6.
ChanKYWangWWuJJ, et al.Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990–2010: a systematic review and analysis. Lancet2013; 381: 2016–2023.
7.
XuXChanYHChanQL, et al.Global cerebrovascular burden and long-term clinical outcomes in Asian elderly across the spectrum of cognitive impairment. Int Psychogeriatr2018; 30: 1355–1363.
8.
MeguroKTanakaNNakatsukaM, et al.Vascular lesions in mixed dementia, vascular dementia, and Alzheimer disease with cerebrovascular disease: the Kurihara project. J Neurol Sci2012; 322: 157–160.
9.
ChenCHommaAMokVC, et al.Alzheimer's disease with cerebrovascular disease: current status in the Asia-pacific region. J Intern Med2016; 280: 359–374.
10.
MeguroKTanakaNKasaiM, et al.Prevalence of dementia and dementing diseases in the old-old population in Japan: the Kurihara project. Implications for long-term care insurance data. Psychogeriatrics2012; 12: 226–234.
11.
FitzpatrickALKullerLHIvesDG, et al.Incidence and prevalence of dementia in the cardiovascular health study. J Am Geriat Soc2004; 52: 195–204.
12.
WardlawJMSmithEEBiesselsGJ, et al.Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol2013; 12: 822–838.
13.
EdwardsJDJacovaCSepehryAA, et al.A quantitative systematic review of domain-specific cognitive impairment in lacunar stroke. Neurology2013; 80: 315–322.
14.
ArvanitakisZCapuanoAWLeurgansSE, et al.Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study. Lancet Neurol2016; 15: 934–943.
15.
KimHJYangJJKwonH, et al.Relative impact of amyloid-β, lacunes, and downstream imaging markers on cognitive trajectories. Brain2016; 139: 2516–2527.
16.
ToledoJBArnoldSERaibleK, et al.Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the national Alzheimer’s coordinating centre. Brain2013; 136: 2697–2706.
17.
ChongJSXJangHKimHJ, et al.Amyloid and cerebrovascular burden divergently influence brain functional network changes over time. Neurology2019; 93: e1514–e1525.
18.
ChongJSXLiuSLokeYM, et al.Influence of cerebrovascular disease on brain networks in prodromal and clinical Alzheimer's disease. Brain2017; 140: 3012–3022.
19.
VemuriPLesnickTGPrzybelskiSA, et al.Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain2015; 138: 761–771.
20.
CaoQ-LSunYHuH, et al.Association of cerebral small vessel disease burden with neuropsychiatric symptoms in non-demented elderly: a longitudinal study. J Alzheimers Dis2022; 89: 583–592.
21.
KanCNGyanwaliBHilalS, et al.Neuropsychiatric correlates of small vessel disease progression in incident cognitive decline: independent and interactive effects. J Alzheimers Dis2020; 73: 1053–1062.
22.
MehannaRJankovicJ. Movement disorders in cerebrovascular disease. Lancet Neurol2013; 12: 597–608.
23.
van AgtmaalMJHoubenAJPouwerF, et al.Association of microvascular dysfunction with late-life depression: a systematic review and meta-analysis. JAMA Psychiatry2017; 74: 729–739.
24.
GouwAASeewannAVan Der FlierWM, et al.Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry2011; 82: 126–135.
25.
PrinsNDScheltensP. White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol2015; 11: 157–165.
26.
WuL-YChaiYLCheahIK, et al.Blood-based biomarkers of cerebral small vessel disease. Ageing Res Rev2024; 95: 102247.
27.
ChongJRAshtonNJKarikariTK, et al.Plasma P-tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease. Alzheimers Dement2021; 17: 1649–1662.
28.
ChongJRChaiYLYamATY, et al.Association of plasma GFAP with elevated brain amyloid is dependent on severity of white matter lesions in an Asian cognitively impaired cohort. Alzheimers Dement (Amst)2024; 16: e12576.
29.
ChongJRHilalSAshtonNJ, et al.Brain atrophy and white matter hyperintensities are independently associated with plasma neurofilament light chain in an Asian cohort of cognitively impaired patients with concomitant cerebral small vessel disease. Alzheimers Dement (Amst)2023; 15: e12396.
30.
ChanVTTSunZTangS, et al.Spectral-domain OCT measurements in Alzheimer's disease: a systematic review and meta-analysis. Ophthalmology2019; 126: 497–510.
31.
CheungCYMokVFosterPJ, et al.Retinal imaging in Alzheimer’s disease. J Neurol Neurosurg Psychiatry2021; 92: 983–994.
32.
CheungCYChanVTMokVC, et al.Potential retinal biomarkers for dementia: what is new?Curr Opin Neurol2019; 32: 82–91.
33.
LanctôtKLAmatniekJAncoli-IsraelS, et al.Neuropsychiatric signs and symptoms of Alzheimer's disease: new treatment paradigms. Alzheimers Dement (N Y)2017; 3: 440–449.
34.
CreeseBBrookerHIsmailZ, et al.Mild behavioral impairment as a marker of cognitive decline in cognitively normal older adults. Am J Geriatr Psychiatry2019; 27: 823–834.
35.
Ter TelgteAVan LeijsenEMWiegertjesK, et al.Cerebral small vessel disease: from a focal to a global perspective. Nat Rev Neurol2018; 14: 387–398.
36.
HilalSMokVYounYC, et al.Prevalence, risk factors and consequences of cerebral small vessel diseases: data from three Asian countries. J Neurol Neurosurg Psychiatry2017; 88: 669–674.
37.
CipolliniVTroiliFGiubileiF. Emerging biomarkers in vascular cognitive impairment and dementia: from pathophysiological pathways to clinical application. Int J Mol Sci2019; 20: 2812.
38.
YangJWongAWangZ, et al.Risk factors for incident dementia after stroke and transient ischemic attack. Alzheimers Dement2015; 11: 16–23.
39.
WollenweberFAZietemannVRomingerA, et al.The determinants of dementia after stroke (DEDEMAS) study: protocol and pilot data. Int J Stroke2014; 9: 387–392.
40.
RostNSMeschiaJFGottesmanR, et al.Cognitive impairment and dementia after stroke: design and rationale for the DISCOVERY study. Stroke2021; 52: e499–e516.
41.
WilcockDJichaGBlackerD, et al.MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols. Alzheimers Dement2021; 17: 704–715.
42.
LuHKashaniAHArfanakisK, et al.MarkVCID cerebral small vessel consortium: II. Neuroimaging protocols. Alzheimers Dement2021; 17: 716–725.
43.
FolsteinMFFolsteinSEMcHughPR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res1975; 12: 189–198.
44.
ThamWAuchusAPThongM, et al.Progression of cognitive impairment after stroke: one year results from a longitudinal study of Singaporean stroke patients. J Neurol Sci2002; 203–204: 49–52.
45.
JackCRJrAlbertMSKnopmanDS, et al.Introduction to the recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 257–262.
46.
RománGCTatemichiTKErkinjunttiT, et al.Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN international workshop. Neurology1993; 43: 250–260.
47.
BrottTAdamsHPJrOlingerCP, et al.Measurements of acute cerebral infarction: a clinical examination scale. Stroke1989; 20: 864–870.
48.
HachinskiVIadecolaCPetersenRC, et al.National institute of neurological disorders and stroke-Canadian stroke network vascular cognitive impairment harmonization standards. Stroke2006; 37: 2220–2241.
DongYPangWSLimLB, et al.The informant AD8 is superior to participant AD8 in detecting cognitive impairment in a memory clinic setting. J Alzheimers Dis2013; 35: 159–168.
51.
FazekasFChawlukJBAlaviA, et al.MR Signal abnormalities at 1.5T in Alzheimer's dementia and normal aging. Am J Roentgenol1987; 149: 351–356.
52.
WahlundL-OBarkhofFFazekasF, et al.A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke2001; 32: 1318–1322.
53.
CordonnierCPotterGMJacksonCA, et al.Improving interrater agreement about brain microbleeds: development of the brain observer MicroBleed scale (BOMBS). Stroke2009; 40: 94–99.
54.
HilalSSainiMTanCS, et al.Intracranial stenosis, cerebrovascular diseases, and cognitive impairment in Chinese. Alzheimer Dis Assoc Disord2015; 29: 12–17.
55.
HilalSSikkingEShaikMA, et al.Cortical cerebral microinfarcts on 3T MRI: a novel marker of cerebrovascular disease. Neurology2016; 87: 1583–1590.
56.
de BoerRVroomanHAIkramMA, et al.Accuracy and reproducibility study of automatic MRI brain tissue segmentation methods. Neuroimage2010; 51: 1047–1056.
57.
VroomanHACocoscoCAVan Der LijnF, et al.Multi-spectral brain tissue segmentation using automatically trained k-nearest-neighbor classification. Neuroimage2007; 37: 71–81.
58.
MutsaertsHJPetrJGrootP, et al.ExploreASL: a collaborative effort to process and explore multi-center ASL data. In: ISMRM’19: Proceedings of the ISMRM 27th annual meeting & exhibition, 2019, p.2705.
59.
ZhouJGreiciusMDGennatasED, et al.Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer’s disease. Brain2010; 133: 1352–1367.
60.
GoodCDJohnsrudeISAshburnerJ, et al.A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage2001; 14: 21–36.
61.
FischlBSerenoMIDaleAM. Cortical surface-based analysis: II: inflation, flattening, and a surface-based coordinate system. Neuroimage1999; 9: 195–207.
62.
WangCJiFHongZ, et al.Disrupted salience network functional connectivity and white-matter microstructure in persons at risk for psychosis: findings from the LYRIKS study. Psychol Med2016; 46: 2771–2783.
63.
JenkinsonMBeckmannCFBehrensTE, et al.Fsl. Neuroimage2012; 62: 782–790.
64.
PasternakOSochenNGurY, et al.Free water elimination and mapping from diffusion MRI. Magn Reson Med2009; 62: 717–730.
65.
JiFPasternakOLiuS, et al.Distinct white matter microstructural abnormalities and extracellular water increases relate to cognitive impairment in Alzheimer's disease with and without cerebrovascular disease. Alzheimers Res Ther2017; 9: 63.
66.
YeoBTKrienenFMSepulcreJ, et al.The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J Neurophysiol2011; 106: 1125–1165.
67.
HachinskiVCIliffLDZilhkaE, et al.Cerebral blood flow in dementia. Arch Neurol1975; 32: 632–637.
68.
MorrisJC. The clinical dementia rating (CDR): current version and scoring rules. Neurology1993; 43: 2412–2414.
69.
BlessedGTomlinsonBERothM. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry1968; 114: 797–811.
70.
FoulkesMAWolfPAPriceTR, et al.The stroke data bank: design, methods, and baseline characteristics. Stroke1988; 19: 547–554.
71.
GélinasIGauthierLMcIntyreM, et al.Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther1999; 53: 471–481.
72.
WadeDTCollinC. The Barthel ADL Index: a standard measure of physical disability?Int Disabil Stud1988; 10: 64–67.
73.
GalvinJERoeCMPowlishtaKK, et al.The AD8: a brief informant interview to detect dementia. Neurology2005; 65: 559–564.
74.
GalvinJE. The quick dementia rating system (QDRS): a rapid dementia staging tool. Alzheimers Dement (Amst)2015; 1: 249–259.
75.
TombaughTNMcIntyreNJ. The Mini-mental state examination: a comprehensive review. J Am Geriatr Soc1992; 40: 922–935.
76.
NasreddineZSPhillipsNABédirianV, et al.The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc2005; 53: 695–699.
77.
FarrellBGodwinJRichardsS, et al.The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry1991; 54: 1044–1054.
78.
JormAF. A short form of the informant questionnaire on cognitive decline in the elderly (IQCODE): development and cross-validation. Psychol Med1994; 24: 145–153.
79.
CummingsJLMegaMGrayK, et al.The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology1994; 44: 2308–2314.
80.
ChuaJLiCHoLKH, et al.A multi-regression framework to improve diagnostic ability of optical coherence tomography retinal biomarkers to discriminate mild cognitive impairment and Alzheimer's disease. Alzheimers Res Ther2022; 14: 41.
81.
CheungCYWongWLEHilalS, et al.Deep-learning retinal vessel calibre measurements and risk of cognitive decline and dementia. Brain Commun2022; 4: fcac212.
82.
SarkarNChaudhuriB. An efficient differential box-counting approach to compute fractal dimension of image. IEEE Transactions Syst Man Cybernetics1994; 24: 115–120.
83.
WeinsteinBEVentryIM. Audiometric correlates of the hearing handicap inventory for the elderly. J Speech Hear Disord1983; 48: 379–384.
84.
WeaverNAZhaoLBiesbroekJM, et al.The meta VCI map consortium for meta-analyses on strategic lesion locations for vascular cognitive impairment using lesion-symptom mapping: design and multicenter pilot study. Alzheimers Dement (Amst)2019; 11: 310–326.
85.
GiorgioJTannaAMalpettiM, et al.A robust harmonization approach for cognitive data from multiple aging and dementia cohorts. Alzheimers Dement (Amst)2023; 15: e12453.
86.
PangTChongEJYWongZX, et al.Validation of the informant quick dementia rating system (QDRS) among older adults in Singapore. J Alzheimers Dis2022; 89: 1323–1330.
87.
ChewKAChongEJYChenCLH, et al.Psychometric properties of the national institute of neurological disorders and stroke and Canadian stroke network neuropsychological battery in an Asian older adult sample. J Am Med Dir Assoc2020; 21: 879–883.e871.
88.
DongYLingMTYNgKET, et al.The clinical utility of the TYM and RBANS in a one-stop memory clinic in Singapore: a pilot study. J Geriatr Psychiatry Neurol2019; 32: 68–73.
89.
PhuaAKSHiuSKWGohWK, et al.Low accuracy of brief cognitive tests in tracking longitudinal cognitive decline in an Asian elderly cohort. J Alzheimers Dis2018; 62: 409–416.
90.
XuXChanQLHilalS, et al.The diagnostic utility of the NINDS-CSN neuropsychological battery in memory clinics. Dement Geriatr Cogn Dis Extra2016; 6: 276–282.
91.
XuXChongEHilalS, et al.Beyond screening: can the mini-mental state examination be used as an exclusion tool in a memory clinic?Diagnostics2015; 5: 475–486.
92.
DongYThompsonCLTanSHJ, et al.Test-retest reliability, convergent validity and practice effects of the RBANS in a memory clinic setting: a pilot study. Open J Med Psychol2013; 2: 11.
93.
SimMADoeckeJDLiewOW, et al.Plasma proteomics for cognitive decline and dementia—A Southeast Asian cohort study. Alzheimers Dement2025; 21: e14577.
94.
SrikrishnaMAshtonNJMoscosoA, et al.CT-Based volumetric measures obtained through deep learning: association with biomarkers of neurodegeneration. Alzheimers Dement2024; 20: 629–640.
95.
FollosoMCVillarazaSGYi-WenL, et al.The AHA/ASA and DSM-V diagnostic criteria for vascular cognitive impairment identify cases with predominant vascular pathology. Int J Stroke2024; 19: 925–934.
96.
LeeLYVaghariDBurkhartMC, et al.Robust and interpretable AI-guided marker for early dementia prediction in real-world clinical settings. EClinicalMedicine2024; 74: 102725.
97.
LiRHarshfieldELBellS, et al.Predicting incident dementia in cerebral small vessel disease: comparison of machine learning and traditional statistical models. Cereb Circ Cogn Behav2023; 5: 100179.
98.
CheungCYRanARWangS, et al.A deep learning model for detection of Alzheimer's disease based on retinal photographs: a retrospective, multicentre case-control study. Lancet Digit Health2022; 4: e806–e815.
99.
AnLChenJChenP, et al.Goal-specific brain MRI harmonization. Neuroimage2022; 263: 119570.
100.
LiuHNaiYHSaridinF, et al.Improved amyloid burden quantification with nonspecific estimates using deep learning. Eur J Nucl Med Mol Imaging2021; 48: 1842–1853.
101.
YuenVRanAShiJ, et al.Deep-learning–based pre-diagnosis assessment module for retinal photographs: a multicenter study. Transl Vis Sci Technol2021; 10: 16–16.
102.
ChuaJLiCAntochiF, et al.Utilizing deep learning to predict Alzheimer's disease and mild cognitive impairment with optical coherence tomography. Alzheimers Dement (Amst)2025; 17: e70041.
103.
AnLZhangCWulanN, et al.Deepresbat: deep residual batch harmonization accounting for covariate distribution differences. Med Image Anal2025; 99: 103354.
104.
PetersenMCoenenMDeCarliC, et al.Enhancing cognitive performance prediction by white matter hyperintensity connectivity assessment. Brain2024; 147: 4265–4279.
105.
EgleMHilalSTuladharAM, et al.Determining the OPTIMAL DTI analysis method for application in cerebral small vessel disease. Neuroimage Clin2022; 35: 103114.
106.
de Brito RobaloBMde LucaAChenC, et al.Improved sensitivity and precision in multicentre diffusion MRI network analysis using thresholding and harmonization. Neuroimage Clin2022; 36: 103217.
107.
de Brito RobaloBMBiesselsGJChenC, et al.Diffusion MRI harmonization enables joint-analysis of multicentre data of patients with cerebral small vessel disease. Neuroimage Clin2021; 32: 102886.
108.
TanakaTStephensonMCNaiYH, et al.Improved quantification of amyloid burden and associated biomarker cut-off points: results from the first amyloid Singaporean cohort with overlapping cerebrovascular disease. Eur J Nucl Med Mol Imaging2020; 47: 319–331.
109.
KuijfHJBiesbroekJMDe BresserJ, et al.Standardized assessment of automatic segmentation of white matter hyperintensities and results of the WMH segmentation challenge. IEEE Trans Med Imaging2019; 38: 2556–2568.
110.
LimCZJZhangYChenY, et al.Subtyping of circulating exosome-bound amyloid β reflects brain plaque deposition. Nat Commun2019; 10: 1144.
111.
ReilhacAMeridaIIraceZ, et al.Development of a dedicated rebinner with rigid motion correction for the mMR PET/MR scanner, and validation in a large cohort of (11)C-PIB scans. J Nucl Med2018; 59: 1761–1767.
112.
ThiagarajanSShaikMAVenketasubramanianN, et al.Coronal CT is comparable to MR imaging in aiding diagnosis of dementia in a memory clinic in Singapore. Alzheimer Dis Assoc Disord2018; 32: 94–100.
113.
WangYCatindigJAHilalS, et al.Multi-stage segmentation of white matter hyperintensity, cortical and lacunar infarcts. Neuroimage2012; 60: 2379–2388.
114.
BurkhartMCLeeLYVaghariD, et al.Unsupervised multimodal modeling of cognitive and brain health trajectories for early dementia prediction. Sci Rep2024; 14: 10755.
115.
EppenbergerLSLiCWongD, et al.Retinal thickness predicts the risk of cognitive decline over five years. Alzheimers Res Ther2024; 16: 273.
116.
EgleMHilalSTuladharAM, et al.Prediction of dementia using diffusion tensor MRI measures: the OPTIMAL collaboration. J Neurol Neurosurg Psychiatry2022; 93: 14–23.
117.
TanCHChewJZhangL, et al.Differential effects of white matter hyperintensities and regional amyloid deposition on regional cortical thickness. Neurobiol Aging2022; 115: 12–19.
118.
BoomsmaJMFExaltoLGBarkhofF, et al.Prediction of poor clinical outcome in vascular cognitive impairment: TRACE-VCI study. Alzheimers Dement (Amst)2020; 12: e12077.
119.
ChongJRHilalSTanBY, et al.Clinical utility of plasma p-tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease. Alzheimers Dement2025; 21: e14502.
120.
SimMAThamYCNusinoviciS, et al.A deep-learning retinal aging biomarker for cognitive decline and incident dementia. Alzheimers Dement2025; 21: e14601.
121.
KanCNHilalSXuX, et al.Comorbid cerebrovascular and neurodegenerative burden in mild behavioral impairment and their impact on clinical trajectory. Acta Neuropsychiatr2025; 37: 1–22.
122.
ZhaoXXuXYanY, et al.Independent and joint associations of cardiometabolic multimorbidity and depression on cognitive function: findings from multi-regional cohorts and generalisation from community to clinic. Lancet Reg Health West Pac2024; 51: 101198.
123.
TeohNSNGyanwaliBLaiMKP, et al.Association of interleukin-6 and interleukin-8 with cognitive decline in an Asian memory clinic population. J Alzheimers Dis2023; 92: 445–455.
124.
WuLYCheahIKChongJR, et al.Low plasma ergothioneine levels are associated with neurodegeneration and cerebrovascular disease in dementia. Free Radic Biol Med2021; 177: 201–211.
125.
KanCNCanoJZhaoX, et al.Prevalence, clinical correlates, cognitive trajectories, and dementia risk associated with mild behavioral impairment in Asians. J Clin Psychiatry2022; 83: 21m14105.
126.
ChuaJZhangZWongD, et al.Age-related eye diseases in individuals with mild cognitive impairment and Alzheimer's disease. Front Aging Neurosci2022; 14: 933853.
127.
KanCNXuXSchmettererL, et al.Interactions of comorbid neuropsychiatric subsyndromes with neurodegenerative and cerebrovascular pathologies on cognition. Neurobiol Aging2022; 109: 239–246.
128.
GyanwaliBLuiBTanCS, et al.Cerebral microbleeds and white matter hyperintensities are associated with cognitive decline in an Asian memory clinic study. Curr Alzheimer Res2021; 18: 399–413.
129.
LimMJRTanCSGyanwaliB, et al.The effect of intracranial stenosis on cognitive decline in a memory clinic cohort. Eur J Neurol2021; 28: 1829–1839.
130.
XuXNi KanCLi-Hsian ChenC, et al.Long-term neurobehavioral correlates of brain cortical microinfarcts in a memory clinic cohort in Singapore. Int J Stroke2022; 17: 218–225.
131.
HilalSTanCSvan VeluwSJ, et al.Cortical cerebral microinfarcts predict cognitive decline in memory clinic patients. J Cereb Blood Flow Metab2020; 40: 44–53.
132.
ChuaXYChaiYLChewWS, et al.Immunomodulatory sphingosine-1-phosphates as plasma biomarkers of Alzheimer's disease and vascular cognitive impairment. Alzheimers Res Ther2020; 12: 122.
133.
ZhangLMakEReilhacA, et al.Longitudinal trajectory of amyloid-related hippocampal subfield atrophy in nondemented elderly. Hum Brain Mapp2020; 41: 2037–2047.
134.
GyanwaliBHilalSVenketasubramanianN, et al.Hearing handicap in Asian patients with dementia. Am J Otolaryngol2020; 41: 102377.
135.
GyanwaliBShaikMATanBY, et al.Risk factors for and clinical relevance of incident and progression of cerebral small vessel disease markers in an Asian memory clinic population. J Alzheimers Dis2019; 67: 1209–1219.
136.
JiFPasternakONgKK, et al.White matter microstructural abnormalities and default network degeneration are associated with early memory deficit in Alzheimer's disease continuum. Sci Rep2019; 9: 4749.
137.
YatawaraCLeeDNgKP, et al.Mechanisms linking white matter lesions, tract integrity, and depression in Alzheimer disease. Am J Geriatr Psychiatry2019; 27: 948–959.
138.
WangJKhosrowabadiRNgKK, et al.Alterations in brain network topology and structural-functional connectome coupling relate to cognitive impairment. Front Aging Neurosci2018; 10: 404.
139.
VipinALokeYMLiuS, et al.Cerebrovascular disease influences functional and structural network connectivity in patients with amnestic mild cognitive impairment and Alzheimer's disease. Alzheimers Res Ther2018; 10: 82.
140.
QiuYLiuSHilalS, et al.Inter-hemispheric functional dysconnectivity mediates the association of corpus callosum degeneration with memory impairment in AD and amnestic MCI. Sci Rep2016; 6: 32573.
141.
PhuaAKSGohWKSuministradoSP, et al.Changing patterns of patient characteristics in a memory clinic in Singapore. J Am Med Direct Assoc2016; 17: 863.e9–863.e14.
142.
ThongJYJDuJRatnarajahN, et al.Abnormalities of cortical thickness, subcortical shapes, and white matter integrity in subcortical vascular cognitive impairment. Hum Brain Mapp2014; 35: 2320–2332.
143.
SainiMIkramKHilalS, et al.Silent stroke: not listened to rather than silent. Stroke2012; 43: 3102–3104.
144.
KanCNCoenenMXuX, et al.Tract-specific white matter hyperintensities and neuropsychiatric syndromes: a multicentre memory clinic study. J Neurol Neurosurg Psychiatry2025; 96: 697–704.
145.
LiaoYChongJRKanCN, et al.Plasma NfL, P-tau181, and P-tau181/Aβ42 ratio in predicting mild behavioral impairment in dementia-free multiethnic Asian older adults with mixed pathology in a 5-year clinical cohort. J Clin Psychiatry2025; 86: 24m15558.
146.
RobertCLingL-HTanES, et al.Longitudinal associations of carotid artery stiffness with progression of cerebrovascular disease, incident dementia and cognitive decline in older adults. J Prev Alzheimers Dis2025; 12: 100127.
147.
CoenenMde KortFAWeaverNA, et al.Strategic white matter hyperintensity locations associated with post-stroke cognitive impairment: a multicenter study in 1568 stroke patients. Int J Stroke2024; 19: 916–924.
148.
BiesbroekJMCoenenMDeCarliC, et al.Amyloid pathology and vascular risk are associated with distinct patterns of cerebral white matter hyperintensities: a multicenter study in 3132 memory clinic patients. Alzheimers Dement2024; 20: 2980–2989.
149.
Del BruttoVJKhasiyevFLiuM, et al.Association of brain arterial diameters with demographic and anatomical factors in a multi-national pooled analysis of cohort studies. Neuroradiol J2024; 37: 304–313.
150.
HuangJOhMRobertC, et al.Loss of white matter integrity mediates the association between cortical cerebral microinfarcts and cognitive dysfunction: a longitudinal study. J Cereb Blood Flow Metab2024; 44: 1723–1732.
151.
RobertCLingL-HTanES, et al.The relative associations of aortic and carotid artery stiffness with CeVD and cognition. J Cereb Blood Flow Metab2025; 45: 498–509.
152.
CuiJRobertCTehCM, et al.Interactive effect of diabetes mellitus and subclinical MRI markers of cerebrovascular disease on cognitive decline and incident dementia: a memory-clinic study. Alzheimers Res Ther2024; 16: 214.
153.
SimMATanESChanSP, et al.Associations of circulating platelet endothelial cell adhesion molecule-1 levels with progression of cerebral small-vessel disease, cognitive decline, and incident dementia. J Am Heart Assoc2024; 13: e035133.
154.
ChongJSXJiFHilalS, et al.Additive effects of cerebrovascular disease functional connectome phenotype and plasma p-tau181 on longitudinal neurodegeneration and cognitive outcomes. Alzheimers Dement2024; 20: 8739–8757.
155.
ZhangYLiaoYYanY, et al.Associations of neurocognitive and neuropsychiatric patterns with brain structural biomarkers and dementia risk: a latent class analysis. J Alzheimers Dis2025; 103: 256–267.
156.
JaliVZhangQChongJR, et al.Diagnosis of cognitive impairment and dementia: blood plasma and optical coherence tomography. Brain Commun2024; 7: fcae472.
157.
ZhangHWenHZhaoX, et al.Cardiometabolic multimorbidity and neuropsychiatric disturbances in multiregional older adults. Alzheimers Dement (Amst)2024; 16: e70007.
158.
HilalSCheungCYWongTY, et al.Retinal parameters, cortical cerebral microinfarcts, and their interaction with cognitive impairment. Int J Stroke2023; 18: 70–77.
159.
SalaiKHTWuLYChongJR, et al.Elevated soluble TNF-receptor 1 in the serum of predementia subjects with cerebral small vessel disease. Biomolecules2023; 13: 525.
160.
ChaiYLRajeevVPohL, et al.Chronic cerebral hypoperfusion alters the CypA-EMMPRIN-gelatinase pathway: implications for vascular dementia. J Cereb Blood Flow Metab2023; 43: 722–735.
161.
JiFChaiYLLiuS, et al.Associations of blood cardiovascular biomarkers with brain free water and its relationship to cognitive decline: a diffusion-MRI study. Neurology2023; 101: e151–e163.
162.
ChaiYLLiangNHPChongJR, et al.Serum cathepsin D is a potential biomarker for Alzheimer's disease dementia and cognitive decline. J Alzheimers Dis2023; 91: 989–998.
163.
ChuaXYTortaFChongJR, et al.Lipidomics profiling reveals distinct patterns of plasma sphingolipid alterations in Alzheimer’s disease and vascular dementia. Alzheimers Res Ther2023; 15: 214.
164.
MakEZhangLTanCH, et al.Longitudinal associations between β-amyloid and cortical thickness in mild cognitive impairment. Brain Commun2023; 5: fcad192.
165.
KanCNHuangXZhangL, et al.Comorbid amyloid with cerebrovascular disease in domain-specific cognitive and neuropsychiatric disturbances: a cross-sectional memory clinic study. Neurobiol Aging2023; 132: 47–55.
166.
RobertCLingLHTanESJ, et al.Effects of carotid artery stiffness on cerebral small-vessel disease and cognition. J Am Heart Assoc2022; 11: e027295.
167.
FerroDAKuijfHJHilalS, et al.Association between cerebral cortical microinfarcts and perilesional cortical atrophy on 3 T MRI. Neurology2022; 98: e612–e622.
168.
GyanwaliBTanCSPetrJ, et al.Arterial spin-labeling parameters and their associations with risk factors, cerebral small-vessel disease, and etiologic subtypes of cognitive impairment and dementia. AJNR Am J Neuroradiol2022; 43: 1418–1423.
169.
SaridinFNChewKAReilhacA, et al.Cerebrovascular disease in suspected non-Alzheimer's pathophysiology and cognitive decline over time. Eur J Neurol2022; 29: 1922–1929.
170.
GyanwaliBMutsaertsHJTanCS, et al.Association of arterial spin labeling parameters with cognitive decline, vascular events, and mortality in a memory-clinic sample. Am J Geriatr Psychiatry2022; 30: 1298–1309.
171.
LimMJRTanJGyanwaliB, et al.The associations between intracranial stenosis, brain amyloid-beta, and cognition in a memory clinic sample. Alzheimer Dis Assoc Disord2022; 36: 327–334.
172.
ChaiYLChongJRRaquibAR, et al.Plasma osteopontin as a biomarker of Alzheimer’s disease and vascular cognitive impairment. Sci Rep2021; 11: 4010.
173.
HilalSMutsaertsHFerroDA, et al.The effects of intracranial stenosis on cerebral perfusion and cognitive performance. J Alzheimers Dis2021; 79: 1369–1380.
174.
GyanwaliBCaiCXTChenC, et al.The effects of mean of visit-to-visit blood pressure on incident brain vascular lesions and functional-cognitive decline. J Alzheimers Dis2021; 82: 561–573.
175.
SaridinFNHilalSVillarazaSG, et al.Brain amyloid β, cerebral small vessel disease, and cognition: a memory clinic study. Neurology2020; 95: e2845–e2853.
176.
FerroDAMutsaertsHJHilalS, et al.Cortical microinfarcts in memory clinic patients are associated with reduced cerebral perfusion. J Cereb Blood Flow Metab2020; 40: 1869–1878.
177.
TanCHHilalSXuX, et al.MRI Markers of mixed pathology and cognitive impairment in multiethnic Asians. J Alzheimers Dis2020; 73: 1501–1509.
178.
VillarazaSTangSSGyanwaliB, et al.The association of Libra index with MRI cerebrovascular disease and cognition in a Singaporean memory clinic cohort (AMSA-SINGAPORE). J Asian Med Stud Assoc2020; 8: 20–22.
179.
GyanwaliBVroomanHVenketasubramanianN, et al.Cerebral small vessel disease and enlarged perivascular spaces-data from memory clinic and population-based settings. Front Neurol2019; 10: 669.
180.
GyanwaliBShaikMATanCS, et al.Mixed-location cerebral microbleeds as a biomarker of neurodegeneration in a memory clinic population. Aging (Albany NY)2019; 11: 10581–10596.
181.
ZhuYHilalSChaiYL, et al.Serum hepatocyte growth factor is associated with small vessel disease in Alzheimer's dementia. Front Aging Neurosci2018; 10: 8.
182.
HilalSChaiYLvan VeluwS, et al.Association between subclinical cardiac biomarkers and clinically manifest cardiac diseases with cortical cerebral microinfarcts. JAMA Neurol2017; 74: 403–410.
183.
LiuSOngYTHilalS, et al.The association between retinal neuronal layer and brain structure is disrupted in patients with cognitive impairment and Alzheimer's disease. J Alzheimers Dis2016; 54: 585–595.
184.
HilalSChaiYLIkramMK, et al.Markers of cardiac dysfunction in cognitive impairment and dementia. Medicine (Baltimore)2015; 94: e297.
185.
HilalSAminSMVenketasubramanianN, et al.Subcortical atrophy in cognitive impairment and dementia. J Alzheimers Dis2015; 48: 813–823.
186.
WuLYChongJRChongJPC, et al.Serum placental growth factor as a marker of cerebrovascular disease burden in Alzheimer's disease. J Alzheimers Dis2024; 97: 1289–1298.
187.
ChiaRSLMintaKWuLY, et al.Serum brevican as a biomarker of cerebrovascular disease in an elderly cognitively impaired cohort. Biomolecules2024; 14: 75.
188.
ChaiYLStrohmLZhuY, et al.Extracellular vesicle-enriched miRNA-biomarkers show improved utility for detecting Alzheimer’s disease dementia and medial temporal atrophy. J Alzheimers Dis2024; 99: 1317–1331.
189.
NgYLTanCSEgleM, et al.The association of diffusion tensor MRI measures of normal appearing white matter and cognition. Cereb Circ Cogn Behav2023; 5: 100174.
190.
CoenenMBiesselsGJDeCarliC, et al.Spatial distributions of white matter hyperintensities on brain MRI: a pooled analysis of individual participant data from 11 memory clinic cohorts. Neuroimage Clin2023; 40: 103547.
191.
CoenenMKuijfHJHuenges WajerIMC, et al.Strategic white matter hyperintensity locations for cognitive impairment: a multicenter lesion-symptom mapping study in 3525 memory clinic patients. Alzheimers Dement2023; 19: 2420–2432.
192.
WuLYKanCNCheahIK, et al.Low plasma ergothioneine predicts cognitive and functional decline in an elderly cohort attending memory clinics. Antioxidants (Basel)2022; 11: 1717.
193.
TanakaTGyanwaliBVillarazaSG, et al.The association between standard electrocardiography and cerebral small vessel disease in a memory clinic study. J Alzheimers Dis2022; 86: 1093–1105.
194.
GyanwaliBLaiMKPLuiB, et al.Blood-based cardiac biomarkers and the risk of cognitive decline, cerebrovascular disease, and clinical events. Stroke2021; 52: 2275–2283.
195.
ZhangLBiesselsGJHilalS, et al.Cerebral microinfarcts affect brain structural network topology in cognitively impaired patients. J Cereb Blood Flow Metab2021; 41: 105–115.
196.
TanakaTRuifenJCNaiYH, et al.Head-to-head comparison of amplified plasmonic exosome Aβ42 platform and single-molecule array immunoassay in a memory clinic cohort. Eur J Neurol2021; 28: 1479–1489.
197.
ChuaJHuQKeM, et al.Retinal microvasculature dysfunction is associated with Alzheimer's disease and mild cognitive impairment. Alzheimers Res Ther2020; 12: 161.
198.
ZhangLZuoXNNgKK, et al.Distinct BOLD variability changes in the default mode and salience networks in Alzheimer's disease spectrum and associations with cognitive decline. Sci Rep2020; 10: 6457.
199.
AkibaCGyanwaliBVillarazaS, et al.The prevalence and clinical associations of disproportionately enlarged subarachnoid space hydrocephalus (DESH), an imaging feature of idiopathic normal pressure hydrocephalus in community and memory clinic based Singaporean cohorts. J Neurol Sci2020; 408: 116510.
200.
GyanwaliBShaikMAVenketasubramanianN, et al.Mixed-location cerebral microbleeds: an imaging biomarker for cerebrovascular pathology in cognitive impairment and dementia in a memory clinic population. J Alzheimers Dis2019; 71: 1309–1320.
201.
ZhuYChaiYLHilalS, et al.Serum IL-8 is a marker of white-matter hyperintensities in patients with Alzheimer's disease. Alzheimers Dement (Amst)2017; 7: 41–47.
202.
HilalSXuXIkramMK, et al.Intracranial stenosis in cognitive impairment and dementia. J Cereb Blood Flow Metab2017; 37: 2262–2269.
203.
LohEHOngYTVenketasubramanianN, et al.Repeatability and reproducibility of retinal neuronal and axonal measures on spectral-domain optical coherence tomography in patients with cognitive impairment. Front Neurol2017; 8: 359.
204.
Gallart-PalauXLeeBSAdavSS, et al.Gender differences in white matter pathology and mitochondrial dysfunction in Alzheimer’s disease with cerebrovascular disease. Mol Brain2016; 9: 27.
205.
BiesbroekJMWeaverNAHilalS, et al.Impact of strategically located white matter hyperintensities on cognition in memory clinic patients with small vessel disease. PLoS One2016; 11: e0166261.
206.
ChaiYLHilalSChongJPC, et al.Growth differentiation factor-15 and white matter hyperintensities in cognitive impairment and dementia. Medicine (Baltimore)2016; 95: e4566.
207.
ChaiYLYeoHKWangJ, et al.Apolipoprotein ɛ4 is associated with dementia and cognitive impairment predominantly due to Alzheimer's disease and not with vascular cognitive impairment: a Singapore-based cohort. J Alzheimers Dis2016; 51: 1111–1118.
208.
CheungC-lOngYTHilalS, et al.Retinal ganglion cell analysis using high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis2015; 45: 45–56.
209.
van VeluwSJHilalSKuijfHJ, et al.Cortical microinfarcts on 3T MRI: clinical correlates in memory-clinic patients. Alzheimers Dement2015; 11: 1500–1509.
210.
XuXHilalSCollinsonSL, et al.Association of magnetic resonance imaging markers of cerebrovascular disease burden and cognition. Stroke2015; 46: 2808–2814.
211.
SainiMSuministradoMSHilalS, et al.Prevalence and risk factors of acute incidental infarcts. Stroke2015; 46: 2722–2727.
212.
WongMYChenCL-HOngY-T, et al.High prevalence of undiagnosed eye diseases in individuals with dementia. J Am Geriatr Soc2015; 63: 192–194.
213.
CheungC-lOngYTIkramMK, et al.Microvascular network alterations in the retina of patients with Alzheimer's disease. Alzheimers Dement2014; 10: 135–142.
214.
MiuraYMiyajiKChaiYL, et al.Autoantibodies to GM1 and GQ1bα are not biological markers of Alzheimer's disease. J Alzheimers Dis2014; 42: 1165–1169.
215.
DongYGanDZQTaySZ, et al.Patterns of neuropsychological impairment in Alzheimer's disease and mixed dementia. J Neurol Sci2013; 333: 5–8.
216.
SkrobotOABlackSEChenC, et al.Progress toward standardized diagnosis of vascular cognitive impairment: guidelines from the vascular impairment of cognition classification consensus study. Alzheimers Dement2018; 14: 280–292.
217.
SkrobotOAO'BrienJBlackS, et al.The vascular impairment of cognition classification consensus study. Alzheimers Dement2017; 13: 624–633.
218.
BhallaGTanotoPVipinA, et al.Current status and future directions for the diagnosis and management of mild cognitive impairment in Southeast Asia: a SEACURE consensus paper. J Prev Alzheimer's Disease2025; 12: 100110.
219.
MaillardPLuHArfanakisK, et al.Instrumental validation of free water, peak-width of skeletonized mean diffusivity, and white matter hyperintensities: markVCID neuroimaging kits. Alzheimers Dement (Amst)2022; 14: e12261.
220.
LiuPJiangDAlbertM, et al.Multi-vendor and multisite evaluation of cerebrovascular reactivity mapping using hypercapnia challenge. Neuroimage2021; 245: 118754.
221.
LiuPLinZHazelK, et al.Cerebrovascular reactivity MRI as a biomarker for cerebral small vessel disease–related cognitive decline: multi-site validation in the MarkVCID consortium. Alzheimers Dement2024; 20: 5281–5289.
222.
WollenweberFADärrSMüllerC, et al.Prevalence of amyloid positron emission tomographic positivity in poststroke mild cognitive impairment. Stroke2016; 47: 2645–2648.
223.
LoJWCrawfordJDDesmondDW, et al.Long-term cognitive decline after stroke: an individual participant data meta-analysis. Stroke2022; 53: 1318–1327.
224.
HilalSLiuSWongTY, et al.White matter network damage mediates association between cerebrovascular disease and cognition. J Cereb Blood Flow Metab2021; 41: 1858–1872.
225.
ChongJRAshtonNJKarikariTK, et al.Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. J Neurol Neurosurg Psychiatry2021; 92: 1231–1241.
226.
CheungC-lOngY-TIkramMK, et al.Retinal microvasculature in Alzheimer's disease. J Alzheimers Dis2014; 42: S339–S352.
227.
ChanVTRanARWagnerSK, et al.Value proposition of retinal imaging in Alzheimer’s disease screening: a review of eight evolving trends. Prog Retin Eye Res2024; 103: 101290.
228.
RajeevVChaiYLPohL, et al.Chronic cerebral hypoperfusion: a critical feature in unravelling the etiology of vascular cognitive impairment. Acta Neuropathol Commun2023; 11: 93.
229.
RajeevVFannDYDinhQN, et al.Pathophysiology of blood brain barrier dysfunction during chronic cerebral hypoperfusion in vascular cognitive impairment. Theranostics2022; 12: 1639.
230.
PohLSimWLJoD-G, et al.The role of inflammasomes in vascular cognitive impairment. Mol Neurodegener2022; 17: 1–28.
ChuaXYHoLTXiangP, et al.Preclinical and clinical evidence for the involvement of sphingosine 1-phosphate signaling in the pathophysiology of vascular cognitive impairment. Neuromol Med2021; 23: 47–67.
233.
Van Der FlierWMSkoogISchneiderJA, et al.Vascular cognitive impairment. Nat Rev Dis Primers2018; 4: 18003.
234.
IkramMKCheungCYWongTY, et al.Retinal pathology as biomarker for cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry2012; 83: 917–922.
235.
SathianvichitrKLamoureuxONakadaS, et al.Through the eyes into the brain, using artificial intelligence. Ann Acad Med Singap2023; 52: 88–95.
236.
DueringMBiesselsGJBrodtmannA, et al.Neuroimaging standards for research into small vessel disease—advances since 2013. Lancet Neurol2023; 22: 602–618.
237.
De GuioFJouventEBiesselsGJ, et al.Reproducibility and variability of quantitative magnetic resonance imaging markers in cerebral small vessel disease. J Cereb Blood Flow Metab2016; 36: 1319–1337.
238.
HuangJBiesselsGJde LeeuwF-E, et al.Cerebral microinfarcts revisited: detection, causes, and clinical relevance. Int J Stroke2024; 19: 7–15.
239.
van VeluwSJShihAYSmithEE, et al.Detection, risk factors, and functional consequences of cerebral microinfarcts. Lancet Neurol2017; 16: 730–740.
240.
LamBYKYiuBAmpilE, et al.High burden of cerebral white matter lesion in 9 Asian cities. Sci Rep2021; 11: 11587.
241.
AshfordJWSchmittFA. Modeling the time-course of Alzheimer dementia. Curr Psychiatry Rep2001; 3: 20–28.
242.
SchmittFADavisDGWeksteinDR, et al.“Preclinical” AD revisited: neuropathology of cognitively normal older adults. Neurology2000; 55: 370–376.
243.
LongstrethWTJrBernickCManolioTA, et al.Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the cardiovascular health study. Arch Neurol1998; 55: 1217–1225.
244.
DuboisBHampelHFeldmanHH, et al.Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement2016; 12: 292–323.
245.
ScheltensPBlennowKBretelerMM, et al.Alzheimer's disease. Lancet2016; 388: 505–517.
246.
ScheltensPDe StrooperBKivipeltoM, et al.Alzheimer's disease. Lancet2021; 397: 1577–1590.
247.
RasmussenJLangermanH. Alzheimer’s disease–why we need early diagnosis. Degener Neurol Neuromuscul Dis2019; 9: 123–130.
248.
BurnsDKAlexanderRCWelsh-BohmerKA, et al.Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol2021; 20: 537–547.
249.
KanXDaiWCuiH, et al.Brain network transformer. Adv Neural Inf Process Syst2022; 35: 25586–25599.
250.
KawaharaJBrownCJMillerSP, et al.BrainNetCNN: convolutional neural networks for brain networks; towards predicting neurodevelopment. Neuroimage2017; 146: 1038–1049.
251.
DrysdaleATGrosenickLDownarJ, et al.Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med2017; 23: 28–38.
252.
DongZWuYChenZ, et al.Prompt your brain: scaffold prompt tuning for efficient adaptation of fmri pre-trained model. In: International conference on medical image computing and computer-assisted intervention. Heidelberg, Germany: Springer, 2024, pp.512–521.
253.
DongZWuYXiaoY, et al.Beyond the snapshot: brain tokenized graph transformer for longitudinal brain functional connectome embedding. In: International conference on medical image computing and computer-assisted intervention. Heidelberg, Germany: Springer, 2023, pp.348–357.
254.
DongZLiRWuY, et al.Brain-JEPA: brain dynamics foundation model with gradient positioning and spatiotemporal masking. Adv Neural Inf Process Syst2024; 37: 86048–86073.
255.
ZhangCAnLWulanN, et al.Cross-dataset evaluation of dementia longitudinal progression prediction models. Hum Brain Mapp2025; 46: e70280.
256.
TanTWKNguyenK-NZhangC, et al.Evaluation of brain age as a specific marker of brain health. bioRxiv2024; DOI: 10.1101/2024.11.16.623903[Preprint]. Posted November 19, 2024.
257.
KlyucherevTOOlszewskiPShalimovaAA, et al.Advances in the development of new biomarkers for Alzheimer’s disease. Transl Neurodegener2022; 11: 25.
258.
GrovesWCBrandtJSteinbergM, et al.Vascular dementia and Alzheimer's disease: is there a difference?J Neuropsychiatr Clin Neurosci2000; 12: 305–315.
259.
AhangariNFischerCESchweizerTA, et al.Cognitive resilience and severe Alzheimer’s disease neuropathology. Aging Brain2023; 3: 100065.
260.
JoshiMSGalvinJE. Cognitive resilience in brain health and dementia research. J Alzheimers Dis2022; 90: 461–473.
261.
SternYAlbertMBarnesCA, et al.A framework for concepts of reserve and resilience in aging. Neurobiol Aging2023; 124: 100–103.
262.
ShigemizuDAkiyamaSHigakiS, et al.Prognosis prediction model for conversion from mild cognitive impairment to Alzheimer’s disease created by integrative analysis of multi-omics data. Alzheimers Res Therapy2020; 12: 1–12.
263.
Tábuas-PereiraMBaldeirasIDuroD, et al.Prognosis of early-onset vs. late-onset mild cognitive impairment: comparison of conversion rates and its predictors. Geriatrics (Basel)2016; 1: 11.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
